Oncogenic Drivers
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.
Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Do you want to take a closer look?

Understand the importance of biomarkers in the management of your patients with NSCLC

oncogenic drivers oncogenic drivers

Oncogenic alterations and your patients with NSCLC…

>12

oncogenic driver alterations identified1

~50%

of patients like yours may have an oncogenic alteration2,3

≤6%

of patients like yours may have an oncogenic MET alteration4,5

With over a dozen oncogenic drivers discovered for NSCLC, testing your patients has never been more important6

These oncogenic driver mutations occur in approximately 50% of patients with NSCLC, including driver mutations such as KRAS, EGFR, ALK, MET and ROS1 alterations (25%, 15%, 5%, 3% and 2%, respectively*).2,3

Estimated alteration frequency* of select oncogenic driver alterations in your patients with NSCLC (%)1,2
Chart illustrates theprevalence of commonly occurring primary driver alterations in patients withNSCLC, with MET alterationscomprising up to 6% of these patients^1,2^

*Prevalence of gene mutations varies between studies

Find out more about what MET alterations mean for your patients with NSCLC

References and Abbreviations:

Expand all Collapse all

1. Rossell R, Karachaliou N. Lancet 2016; 387:1354–1356.

2. Pakkala S, Ramalingam SS. JCI Insight 2018; 3:e120858. 

3. Grosse A et al. Diagn Pathol 2019; 14:18. 

4. Salgia R. Mol Cancer Ther 2017; 16:555–565.

5. Ikeda S et al. J Hematol Oncol 2018; 11:76.

6. Yoda S et al. Pharmacol Ther 2019; 193:20–30. 

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Continued use of this website indicates that you agree to the terms of our privacy policy and cookie usage. For more information, please review the Privacy Policy

 

OK

Leaving website.

This link will take you to a website to which our Privacy Policy and Conditions may not apply. Merck has no control over the contents and policies of third party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. 

 

 

 

Please check Privacy Policy and Conditions of the linked website.

 

 

 

Do you wish to continue and leave this site?

Are you a healthcare professional?

  

YES

  

 

NO

Not a healthcare professional? Visit our public site

Continue
lightbox image